A
Albiruni Ryan Abdul Razak
Researcher at Princess Margaret Cancer Centre
Publications - 253
Citations - 7154
Albiruni Ryan Abdul Razak is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 39, co-authored 195 publications receiving 5045 citations. Previous affiliations of Albiruni Ryan Abdul Razak include Harvard University & University Health Network.
Papers
More filters
Journal ArticleDOI
A systematic review of immune-related adverse event (irAE) reporting in clinical trials of immune checkpoint inhibitors (ICIs).
TL;DR: A systematic search of citations from MEDLINE, EMBASE and Cochrane databases identified prospective clinical trials involving ICIs in advanced solid tumors from 2003-2013 and identified factors associated with quality reporting.
Journal ArticleDOI
A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study
Abdulazeez Salawu,Aaron R. Hansen,Anna Spreafico,Esmail Mutahar Al-Ezzi,Sheila Webster,Philippe L. Bedard,Jeffrey Doi,Lisa Wang,Lillian L. Siu,Albiruni Ryan Abdul Razak +9 more
TL;DR: Clinical benefit seen in all 3 salivary gland cancers supports the growing evidence for the utility of HER-targeted therapies in the treatment of this specific tumor type.
Journal ArticleDOI
A phase II, open-label, randomized trial of durvalumab (D) with olaparib (O) or cediranib (C) in patients (pts) with leiomyosarcoma (LMS).
O. Ayodele,Ben X Wang,Thomas D Pfister,Esmail Mutahar Al-Ezzi,Hal K. Berman,Aaron R. Hansen,Abha A. Gupta,Anna Spreafico,Limore Arones,Philippe L. Bedard,Lindsay Carlsson,Marcus O. Butler,Benjamin Haibe-Kains,Wei Xu,Lillian L. Siu,Albiruni Ryan Abdul Razak +15 more
TL;DR: Although a cold-to-hot immunophenotype change was not generally seen, changes in tumor infiltrating immune cell subsets were observed in one patient with prolonged stable disease, and these findings support further molecular and immunophenotypes characterization in LMS patients treated with D+O or D+C.
Journal ArticleDOI
A phase II study of dasatanib (BMS 354825) in recurrent or metastatic ckit-expressing adenoid cystic (ACC) and non-ACC malignant salivary glands tumors (MSGT).
Stuart J. Wong,Ezra E.W. Cohen,Theodore Karrison,David N. Hayes,Merrill S. Kies,Kevin J. Cullen,Tawee Tanvetyanon,Athanassios Argiris,Naoko Takebe,Dean Lim,Nabil F. Saba,Francis P. Worden,Jill Gilbert,Heinz-Josef Lenz,Albiruni Ryan Abdul Razak,John D. Roberts,Everett E. Vokes +16 more
TL;DR: Dasatinib is a potent and selective inhibitor of ckit proto-oncogene that acts as a ‘spatially aggregating force’ to knock down the activity of this gene in patients with ACC.
Journal ArticleDOI
Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)
Cindy Yang,Marco A. J. Iafolla,Scott Dashner,W. Xu,Aaron R. Hansen,P. Bedard,Stephanie Lheureux,Anna Spreafico,Albiruni Ryan Abdul Razak,H.-T. Wu,Svetlana Shchegrova,Zhihui (Amy) Liu,Pamela S. Ohashi,Dax Torti,Maggie C. Louie,Himanshu Sethi,Alexey Aleshin,L.L. Siu,Scott V. Bratman,Trevor J. Pugh +19 more
TL;DR: Strong correlations exist between both ctDNAB and ΔctDNA with clinical outcome, suggesting both prognostic and predictive values in pts with mixed solid tumors, according to the investigator-initiated phase II INSPIRE trial.